Wegovy: How to Safely Stop Semaglutide 2.4 mg

Wegovy is the brand name for semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk and given as a once-weekly subcutaneous injection for chronic weight management. It is the same molecule sold as Ozempic at lower doses (up to 2.0 mg) for type 2 diabetes, and it is a different molecule from tirzepatide (Mounjaro/Zepbound), which acts on both GIP and GLP-1 receptors. This article covers stopping the 2.4 mg weight-management formulation specifically.

This is a draft prepared for editorial and qualified medical review. It is pending clinical review.

The short answer

Stopping Wegovy is not physiologically dangerous the way stopping some other chronic medications can be, but it reliably leads to hunger returning and, for most patients, significant weight regain over the following months. In the STEP-4 trial, participants who switched from semaglutide 2.4 mg to placebo after an initial run-in period regained a substantial portion of the weight they had lost within about a year, while those who continued the drug kept losing. This is a pharmacological effect, not a behavioral failure, because the drug's appetite-suppressing action on the brain fades as it clears the body over roughly five weeks. Because the weight-loss effect depends on continued dosing, the decision to stop is best made with a clinician, paired with a plan for monitoring weight, glucose, and cardiometabolic markers afterward.

At a glance

• Drug / Wegovy (semaglutide 2.4 mg subcutaneous injection, once weekly)
• Manufacturer / Novo Nordisk
• FDA-approved indication / chronic weight management in adults, and in adolescents 12 and older, with obesity or overweight plus a weight-related condition
• Half-life / approximately one week, so drug exposure falls gradually rather than abruptly after the last dose
• Rebound risk / weight regain is common after stopping; the STEP-4 trial found participants who switched to placebo regained a large share of their lost weight within a year, while those who continued did not
• FDA approval / June 2021 for adults; expanded to adolescents in December 2022 (verify current label date before publishing)
• Prescription status / prescription only
• Not established / a specific tapering schedule for stopping is not part of the FDA label; any taper described below reflects clinical reasoning about pharmacokinetics, not a labeled or trial-tested protocol

How semaglutide works, and why that matters for stopping it

Semaglutide activates GLP-1 receptors in appetite-regulating regions of the hypothalamus and brainstem, reducing hunger and the reward value of food, while also slowing gastric emptying and affecting insulin and glucagon secretion. At the 2.4 mg dose used for weight management, the central appetite effects are generally considered the main driver of weight loss.

The drug's plasma half-life is approximately one week. After the last injection, drug levels fall by roughly half each week, so full clearance takes about five weeks. Because of this gradual decline, appetite suppression does not disappear overnight. Most patients notice hunger beginning to increase around two to three weeks after their final dose, well before the drug is fully out of the system.

Why weight regain after stopping is common, not a personal failure

Obesity is widely treated in clinical guidelines as a chronic, relapsing condition rather than a temporary state that a course of medication permanently resolves. When semaglutide is cleared from the body, appetite circuits that were suppressed during treatment return toward their pretreatment activity. Metabolic adaptations that occur during weight loss, including a lower resting energy expenditure and changes in hunger-related hormones, do not automatically reverse just because the drug is stopped, and they tend to work against continued weight maintenance.

The STEP-4 trial specifically tested this: participants who had already lost weight on semaglutide 2.4 mg were randomized to either continue the drug or switch to placebo for roughly another year. Those who continued kept losing weight; those switched to placebo regained a large share of what they had lost, and measures such as waist circumference and blood pressure moved in an unfavorable direction. The STEP-1 trial, which established the drug's initial efficacy (reporting substantially greater weight loss on semaglutide than on placebo over 68 weeks), also included follow-up after treatment stopped, with regain concentrated in the first several months off the drug.

Evidence anchor and boundary: the finding that stopping semaglutide 2.4 mg leads to substantial weight regain within about a year is established from randomized controlled trial data (the STEP program), not merely observational reports. What is not established from these trials is the long-term trajectory beyond about one to two years off the drug, or how much a structured taper versus abrupt stopping changes the speed or amount of regain, since no published trial has directly compared tapered and abrupt discontinuation of semaglutide 2.4 mg.

Reported figures for weight loss and regain in the STEP-1 and STEP-4 trials vary between sources and have not been independently confirmed here, so readers should consult the primary trial publications for exact values.

Who has a legitimate reason to stop

Not everyone should stay on Wegovy indefinitely, and some reasons to stop are clear-cut.

Medical contraindications and safety events. The FDA label lists contraindications including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), and describes acute pancreatitis as a serious risk requiring the drug to be stopped (FDA prescribing information, reviewed 2023; confirm current label version before relying on this). Severe gastrointestinal intolerance that persists despite slower dose escalation, and gallbladder disease requiring intervention, are also recognized reasons to stop.

Pregnancy planning. Because semaglutide's effects on fetal development have not been adequately studied in humans, prescribers commonly advise stopping well before a planned pregnancy to allow time for clearance. The specific interval recommended should come from the current label and the prescribing clinician rather than a fixed rule stated here.

Supply and cost barriers. Wegovy has experienced periods of shortage; the FDA drug shortage database tracks current status for semaglutide injection (FDA Drug Shortages Database, status changes over time, so check the date you view it). When a maintenance dose is unavailable, clinicians and patients sometimes have to choose between holding at a lower available dose or stopping.

A patient-initiated trial after sustained behavior change. A minority of patients who have reached their goal and built durable habits attempt a supervised stop. This should be planned with a prescriber and paired with a monitoring schedule, not undertaken alone.

Is there a standard tapering schedule?

The Wegovy label does not specify a required tapering schedule for stopping. Some clinicians use a stepwise dose reduction reasoning from the drug's available strengths (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) and its roughly one-week half-life, on the theory that a gradual step-down may blunt the speed of hunger rebound and give more time to intensify behavioral support. This has not been tested against abrupt stopping in a randomized trial for semaglutide 2.4 mg specifically, so its benefit is plausible but unproven.

An illustrative step-down some clinicians discuss, shown here for education rather than as a prescription:

This schedule is not FDA-mandated and has not itself been validated in a published trial. Actual timing, whether to taper at all, and how quickly to step down should be individualized by the prescribing clinician based on tolerability, comorbidities, and reason for stopping.

During a taper or after abrupt stopping, expect hunger to increase gradually starting around two to three weeks after each reduction, and expect glucose to potentially rise in people with prediabetes or type 2 diabetes, which may require adjusting other diabetes medications.

What "withdrawal" from Wegovy actually looks like

Semaglutide does not cause physical dependence and there is no withdrawal syndrome in the pharmacological sense used for drugs like opioids or benzodiazepines. What patients describe after stopping is the return of hunger, cravings, and sometimes reduced energy, which reflects the reversal of the drug's appetite-suppressing effect rather than a withdrawal reaction. These sensations typically build over the first two to four weeks after the last dose and continue as the drug fully clears over about five weeks.

Clinician conversation and monitoring framework

This is a discussion and monitoring structure to use with a prescriber when planning to stop Wegovy. It distinguishes what comes from the FDA label, what comes from trial evidence, and what is clinical judgment requiring individualization.

Two boundaries matter throughout this process. First, the FDA label establishes contraindications and known serious risks (pancreatitis, thyroid C-cell tumors in animal studies, gallbladder disease) but does not specify how to stop or a required monitoring schedule after stopping. Second, the weight, glucose, and blood pressure thresholds above reflect general guideline targets and clinical reasoning applied to this drug's known regain pattern, not a semaglutide-specific validated cutoff; a clinician may reasonably set different thresholds for an individual patient based on their overall risk profile.

Preserving weight loss without the drug

No behavioral program fully replaces semaglutide's pharmacological effect. In the STEP-1 trial, the lifestyle-counseling-only comparison group lost only a small fraction of what the semaglutide group lost. Still, intensive lifestyle support can slow the rate of regain after stopping.

Reasonable, widely supported components include a modest calorie deficit (commonly cited as roughly 300 to 500 kcal below estimated needs, rather than aggressive restriction that triggers strong compensatory hunger), higher dietary protein intake to support satiety and preserve lean mass, and regular aerobic and resistance exercise consistent with general physical activity guidelines for weight maintenance. None of these strategies has been tested specifically as a post-Wegovy regimen in a controlled trial; they are extrapolated from general obesity medicine and weight-maintenance research, and that extrapolation should be stated plainly to patients rather than presented as semaglutide-specific evidence.

Restarting or switching after stopping

Stopping Wegovy does not have to be permanent. If a patient stopped because of a supply or cost barrier that has resolved, restarting is a reasonable option to discuss. For gaps longer than about four weeks off the drug, prescribers commonly restart from the lowest dose and re-escalate over several months to reduce the risk of gastrointestinal side effects, similar to the original titration; the exact re-escalation schedule should follow current label guidance and the prescriber's judgment rather than a fixed patient-facing rule.

Tirzepatide (marketed as Zepbound for weight management), a dual GIP/GLP-1 receptor agonist, is a separate FDA-approved option for chronic weight management that some patients switch to if they had an inadequate response to semaglutide or are stopping for tolerability reasons. There is no mandatory washout period between these GLP-1-class agents, but tirzepatide has its own titration schedule that needs to be followed. Older, lower-efficacy options such as phentermine/topiramate extended-release, naltrexone/bupropion, and orlistat remain FDA-approved alternatives for patients who cannot access or tolerate GLP-1 receptor agonists, though none has matched semaglutide 2.4 mg's average weight-loss magnitude in published trials.

Special situations that change the calculus

Type 2 diabetes. Stopping a drug that suppresses glucagon and supports insulin secretion can raise fasting glucose. Anyone with type 2 diabetes stopping Wegovy should have their full diabetes regimen reviewed, not just their weight-management plan.

Established cardiovascular disease. A large cardiovascular outcomes trial of semaglutide 2.4 mg (the SELECT trial) found a reduction in major cardiovascular events in adults with established cardiovascular disease and overweight or obesity, without diabetes, over several years of follow-up. Because that cardiovascular benefit appears to depend on continued treatment, patients with known cardiovascular disease who are considering stopping should discuss the tradeoff with their cardiologist or prescriber directly rather than assume the benefit persists after the drug is gone. (Exact effect size should be confirmed against the primary SELECT publication before being quoted precisely.)

Adolescents. Wegovy is FDA-approved for adolescents 12 and older with obesity, based on a dedicated adolescent trial. Discontinuation in this age group should involve a pediatric obesity specialist; regain patterns and long-term effects of stopping have not been studied as extensively in adolescents as in adults, and growth and pubertal status add complexity that adult data cannot address.

When gastrointestinal side effects are the reason to stop

Nausea, vomiting, diarrhea, and constipation are the most common reasons patients stop Wegovy before reaching a weight goal. Before stopping entirely for this reason, it is reasonable to ask a prescriber about slowing the dose-escalation schedule (holding each step longer than the standard four weeks) rather than abandoning treatment outright, since much of this intolerance occurs during escalation rather than at a stable maintenance dose.

Acute pancreatitis is different: persistent, severe abdominal pain radiating to the back is a reason to stop the drug immediately and seek urgent medical evaluation, not to wait for a scheduled follow-up. The label identifies pancreatitis as a risk requiring discontinuation, and it should not be restarted after a confirmed episode.

What is established, what is plausible, and what is not established

Established: Semaglutide 2.4 mg's weight-loss effect depends on continued dosing; stopping leads to substantial weight regain for most patients within about a year, based on randomized trial evidence (STEP-4) rather than only observational reports. The drug has a roughly one-week half-life and no pharmacological withdrawal syndrome.

Plausible but unproven: That a gradual dose taper reduces the speed or severity of hunger rebound and regain compared with abrupt stopping. That a specific calorie, protein, or exercise target preserves more weight after stopping semaglutide specifically, as opposed to general weight-maintenance evidence.

Not established: Long-term (multi-year) outcomes after stopping. Adolescent-specific regain patterns. Any single "best" tapering schedule, since none has been validated in a controlled trial for this drug.

References

• U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf (confirm this reflects the current label version before publication)
• U.S. Food and Drug Administration. Drug Shortages Database, semaglutide injection. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide+Injection&st=c (status changes over time; check date viewed)

Editorial flag for reviewer: numbered journal citations for the STEP-1, STEP-4, SELECT, SURMOUNT-1, and STEP TEENS trials were present in the prior draft version of this article but pointed to identifiers that could not be verified as matching the claims in this review pass. Trial names and general findings have been retained because they are well documented in the obesity medicine literature, but exact percentage figures, sample sizes, and follow-up durations should be re-confirmed against the primary NEJM, JAMA, and Lancet publications and re-cited directly before this page is published.